Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Granulomatous hepatitis with Crohn's disease: a case report.
Suzuki T, Hayakawa Y, Kaneko S, Takenaka K, Watakabe K, Kinowaki Y, Takemoto A, Ohtsuka K, Asahina Y, Okamoto R. Suzuki T, et al. Among authors: hayakawa y. Clin J Gastroenterol. 2024 Mar 19. doi: 10.1007/s12328-024-01937-8. Online ahead of print. Clin J Gastroenterol. 2024. PMID: 38502473
Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog.
Kirino S, Tamaki N, Kaneko S, Kurosaki M, Inada K, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Watakabe K, Okada M, Wang W, Shimizu T, Higuchi M, Takaura K, Maeyashiki C, Yasui Y, Nakanishi H, Tsuchiya K, Itakura J, Takahashi Y, Izumi N. Kirino S, et al. Among authors: hayakawa y. J Gastroenterol Hepatol. 2020 Sep;35(9):1595-1601. doi: 10.1111/jgh.14990. Epub 2020 Feb 11. J Gastroenterol Hepatol. 2020. PMID: 31975419
Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis.
Inada K, Kaneko S, Kurosaki M, Yamashita K, Kirino S, Osawa L, Hayakawa Y, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Itakura J, Takahashi Y, Tsuchiya K, Nakanishi H, Okamoto R, Izumi N. Inada K, et al. Among authors: hayakawa y. JGH Open. 2021 Aug 19;5(9):1085-1091. doi: 10.1002/jgh3.12636. eCollection 2021 Sep. JGH Open. 2021. PMID: 34584979 Free PMC article.
Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice.
Hayakawa Y, Tsuchiya K, Kurosaki M, Yasui Y, Kaneko S, Tanaka Y, Ishido S, Inada K, Kirino S, Yamashita K, Nobusawa T, Matsumoto H, Kakegawa T, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Okamoto R, Izumi N. Hayakawa Y, et al. Invest New Drugs. 2022 Apr;40(2):392-402. doi: 10.1007/s10637-021-01185-4. Epub 2021 Sep 29. Invest New Drugs. 2022. PMID: 34586531
Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy.
Sekiguchi S, Tsuchiya K, Yasui Y, Inada K, Kirino S, Yamashita K, Hayakawa Y, Osawa L, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Okamoto R, Kurosaki M, Izumi N. Sekiguchi S, et al. Among authors: hayakawa y. Cancer Rep (Hoboken). 2022 Nov;5(11):e1613. doi: 10.1002/cnr2.1613. Epub 2022 Mar 18. Cancer Rep (Hoboken). 2022. PMID: 35302279 Free PMC article.
Validation of magnetic resonance elastography plus fibrosis-4 for significant fibrosis in nonalcoholic fatty liver disease.
Inada K, Tamaki N, Kurosaki M, Kirino S, Yamashita K, Hayakawa Y, Higuchi M, Takaura K, Kaneko S, Maeyashiki C, Yasui Y, Tsuchiya K, Nakanishi H, Izumi N. Inada K, et al. Among authors: hayakawa y. J Gastroenterol Hepatol. 2022 Sep;37(9):1726-1731. doi: 10.1111/jgh.15893. Epub 2022 Jun 3. J Gastroenterol Hepatol. 2022. PMID: 35587726
Detecting advanced liver fibrosis using ultrasound shear wave velocity measurement in the general population.
Kirino S, Tamaki N, Kurosaki M, Takahashi Y, Higuchi M, Itakura Y, Tanaka Y, Inada K, Ishido S, Yamashita K, Nobusawa T, Matsumoto H, Hayakawa Y, Kakegawa T, Takaura K, Tanaka S, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Okamoto R, Izumi N. Kirino S, et al. Among authors: hayakawa y. Quant Imaging Med Surg. 2023 Oct 1;13(10):6493-6502. doi: 10.21037/qims-23-511. Epub 2023 Aug 28. Quant Imaging Med Surg. 2023. PMID: 37869309 Free PMC article.
Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients.
Kaneko S, Kurosaki M, Inada K, Kirino S, Hayakawa Y, Yamashita K, Osawa L, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Itakura J, Takahashi Y, Tsuchiya K, Nakanishi H, Izumi N. Kaneko S, et al. Among authors: hayakawa y. J Gastroenterol Hepatol. 2021 Oct;36(10):2943-2951. doi: 10.1111/jgh.15563. Epub 2021 Jun 16. J Gastroenterol Hepatol. 2021. PMID: 34057248
Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma.
Matsumoto H, Tsuchiya K, Nakanishi H, Hayakawa Y, Yasui Y, Uchihara N, Suzuki K, Tanaka Y, Miyamoto H, Ishido S, Yamada M, Keitoku T, Nobusawa T, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Tamaki N, Takahashi Y, Kurosaki M, Asahina Y, Okamoto R, Izumi N. Matsumoto H, et al. Among authors: hayakawa y. Cancers (Basel). 2022 Jul 21;14(14):3551. doi: 10.3390/cancers14143551. Cancers (Basel). 2022. PMID: 35884610 Free PMC article.
Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis B.
Kirino S, Tamaki N, Kurosaki M, Kaneko S, Inada K, Tanaka Y, Ishido S, Yamashita K, Nobusawa T, Matsumoto H, Hayakawa Y, Kakegawa T, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, Okamoto R, Izumi N. Kirino S, et al. Among authors: hayakawa y. Hepatol Res. 2023 Jan;53(1):35-42. doi: 10.1111/hepr.13839. Epub 2022 Oct 4. Hepatol Res. 2023. PMID: 36117296
1,162 results